HanAll Biopharma (KRX: 009420.KS), a South Korea-based global biopharmaceutical company, announced on Monday that it has named Christopher W Slavinsky as its new chief business development and legal officer.

Slavinsky has more than 25 years of experience in legal and business development roles within large pharmaceutical companies and small, emerging biotechnology companies. He has served as chief business and legal officer at Coherus BioSciences, and in leadership positions at Pharmacosmos Therapeutics, Prometheus Biosciences, Takeda and Pfizer.

Sean Jeong, MD, MBA, HanAll Biopharma CEO, said, 'Chris brings a wealth of expertise to HanAll with his proven track record at leading biopharmaceutical companies and deep knowledge in legal and business strategy. His experience in driving transformative initiatives and navigating complex regulatory landscapes will be instrumental as we continue to innovate and expand our presence in the industry.'